

Interim Report

January 1 – June 30, 2016

The second quarter in figures

- Total net sales amounted to TSEK 1,855 (918).
- The loss after tax amounted to TSEK 14,468 (10,939).
- The loss per share amounted to SEK 1.75 (1.80).
- The cash flow from current operations was negative in the amount of TSEK 13,112 (13,858).
- Significant margin improvement with gross margin increasing to 30.1% in Q2 (-34.5% Q2 15).

The first half-year in figures

- Total net sales amounted to TSEK 2,921 (1,975).
- The loss after tax amounted to TSEK 26,068 (20,118).
- The loss per share amounted to SEK 3.15 (3.63).
- The cash flow from current operations was negative in the amount of TSEK 24,359 (23,055).
- Significant margin improvement with gross margin increasing to 28.7% (-14.6%).

Important events during the quarter

- Record growth in key market Germany with total sales up 124% and electrode sales volume up 212%.
- SciBase will insource the strategically important production of the disposable electrode from Ginolis. The companies have mutually agreed to transfer the manufacturing to SciBase when Ginolis AB has completed the next milestone in the stepwise automation of the production process.
- As part of the Nevisense PMA-process, a series of inspections were carried out by the US FDA with good results.
- The AGM was held on May 16, 2016.
- SciBase participated in the Euromelanoma week May 9-13, a European initiative to highlight skin-cancer.
- On April 25th, the Annual Report for 2015 was published.

Important events after the end of the period

- A milestone was passed when the hundredth clinic in Germany installed a Nevisense device.

Financial overview

THE GROUP	Apr 1 - June 30		Jan 1 - June 30		July 1 2015 -	
	2016	2015	2016	2015	June 30 2016	Jan 1 - Dec 31
					Rolling-12	2015
Net sales, SEK ths	1 855	918	2 921	1 975	5 097	4 151
Gross margin, %	30,1%	-34,5%	28,7%	-14,6%	24,1%	2,5%
Equity/Asset ratio, %	92,7%	91,4%	92,7%	91,4%	92,7%	95,1%
Net indebtedness, multiple	0,08	0,09	0,08	0,09	0,08	0,05
Cash equivalents, SEK ths	108 786	165 595	108 786	165 595	108 786	133 736
Cashflow from operating activities, SEK ths	-13 112	-13 858	-24 359	-23 055	-47 892	-46 588
Earnings per share (before and after dilution), SEK*	-1,75	-1,80	-3,15	-3,63	-5,73	-6,01
Shareholder's equity per share, SEK*	14,45	27,41	14,45	30,13	14,45	21,09
Average number of shares, 000*	8 285	6 085	8 285	5 535	8 285	6 910
Number of shares at closing of period, 000*	8 285	8 285	8 285	8 285	8 285	8 285
Share price at end of period, SEK	17,20	43,00	17,20	43,00	17,20	31,00
Average number of employees	19	13	19	14	15	14

*Adjusted for in May 2015 performed reversed split, 40:1

Definitions and a glossary are provided on page 16.



Comment by CEO Simon Grant

“Doubled sales and successful audits in the PMA process”

Highlights

- Record sales in the quarter with an increase of 102 % including a 92 % increase in the number of electrodes sold.
- German sales increased in value by 124 % and electrode sales in volume by 212 %.
- 100th clinic in Germany has purchased Nevisense.
- The gross margin continues to improve and reached 30.1 % (-34.5 %).
- SciBase will insource the strategically important production of the disposable electrode from Ginolis.
- Successful completion of audits as part of our US approval process.

Summarizing the second quarter of the year, we can say that it has been an eventful period with most of the Company internally focused on the PMA process and the seven audits performed by FDA. Given that, it was pleasing to see that we still managed to achieve a record sales quarter, both in terms of Nevisense-systems and disposable electrodes. In the second quarter, sales increased by 102 % reaching 1.9 MSEK and the sales of electrodes in volume by 99%. We have also managed to increase our gross margin by four percentage points from the first quarter 2016 to reach 30%.

Sales milestone in Germany

In June the 100th German clinic installed a Nevisense. We now have a reasonably widespread network of clinics offering Nevisense to patients. Being present at 100 clinics is evidence that our method now has clinical and market acceptance in Germany. We believe that this is driving an increased interest in Nevisense from new clinics. We have a good foothold, but we are still at an early stage having penetrated less than 4 % of the private dermatology clinics.

The good results in Germany are the result of our ongoing and focused sales and marketing efforts in the German market. We are however, also making significant efforts to get the other markets generating regular sales.

In May we also participated in the Euromelanoma week in Sweden. This resulted in nine clinics around Sweden being able to offer their patients a Nevisense test.

Product development and manufacturing

As in the last quarter, we continue to work with new product development. This is both about longer-term investigations into additional dermatology clinical applications for our method and shorter horizon projects

to enhance our existing product. The results of this work will be presented during the autumn.

During the second quarter, we also decided to insource the production of our electrodes from the manufacturer Ginolis AB. The production transfer process is now formally completed and the production semi-automated line transferred to SciBase. The production of the electrodes is our most strategic and important process and by fully controlling the process it is easier for us to drive the development of a more cost effective production forward. By integrating the manufacturing of the electrodes into SciBase's operations, we expect to see improvements in both product development and manufacturing of the electrode.

We do not expect the margin to be affected notably short-term by the insourcing. In the longer term we see good opportunities to significantly improve electrode gross margin through better control and streamlining of the production process.

The PMA process

Our PMA process has understandably required a lot of resources. To date we have had a good response from the FDA and we are satisfied with our progress. During the second quarter FDA have performed a total of seven inspections ranging from three days to two weeks in duration. These inspections are customary for a PMA process and include our office here in Stockholm, our production partners and clinics that participated in our clinical trials. In these visits, FDA has inspected many aspects of SciBase and Nevisense such as our development, manufacturing and quality controls as well as our clinical development and trials. The results from the audits have so far been both pleasing and successful. That we have received such positive results from these inspections is a real achievement for SciBase; one that we are very proud of.

The fast pace of the spring will continue and going forward our focus will be on the FDA process, driving our sales growth and on new product development that will strengthen our product offer in the short-term. We are also looking forward to the results from on-going clinical trials, which are expected to be presented during the second half of the year!



Simon Grant, CEO
Stockholm August 19, 2016



SciBase in brief

About SciBase

SciBase is a medical technology company that develops instruments for the detection of skin cancer. The Nevisense® product can detect malignant melanoma, the most dangerous form of skin cancer, directly on the skin without needing to cut away suspect moles. The Company was founded in 1998 by Stig Ollmar, a researcher at The Karolinska Institute. The product is based on comprehensive research and SciBase has conducted the largest study to date on the detection of malignant melanoma, in which Nevisense achieved excellent results. The study was published in May 2014 in the prestigious British Journal of Dermatology. Nevisense is approved for sale in Europe (holding a CE mark) and Australia. Approval by the US FDA is expected, at the earliest, around the end of 2016.

SciBase's headquarters are located in Stockholm, where the company is listed on the Nasdaq First North exchange since June 2, 2015. Avanza is the Company's certified advisor.

Business model

The company's business model is based on customers initially purchasing an instrument (Nevisense) and then buying new tests (electrodes) on an on-going basis. Each electrode can only be used on one patient but on as many as ten moles.



Short facts

- Skin cancer is the most common and fastest-growing form of cancer in the world.
- Malignant melanoma is the most dangerous form of skin cancer with a high mortality rate if not detected early.
- In the United States, expenditure for the treatment of malignant melanoma is approximately USD 3.3 billion annually, equivalent to 41% of expenditure for skin cancer. In recent years, expenditure has increased four-fold.
- Today, some 50-60 million annual examinations for malignant melanoma are performed, of which 5-6 million lead to excisions. Of these, some 93-97% are shown to be benign.
- With SciBase's Nevisense® product, the number of unnecessary interventions can be reduced by up to 40%, representing a reduction of about 1.5-2.5 million interventions annually and thus leading to significant cost savings.
- Nevisense® provides physicians with an objective instrument to support better diagnoses.

" This device gives us better safety in the diagnosis of suspicious lesions. When we do the diagnosis with Nevisense, we have incorporated another safety step, so we do not need to unnecessarily injure and cut the patient." Dr. Christoph Liebich

Excisions of nevi in Sweden

- 100,000 individuals undergo surgery per year
- 150,000 lesions excised per year to detect 3,500 invasive melanomas
- The annual cost is estimated to be over MSEK 300



Second quarter

Net Sales

Net sales for the second quarter of 2016 amounted to TSEK 1,855 (918), an increase of 102%. Of this, sales of instruments accounted for TSEK 696 (432) and sales of tests for TSEK 1,159 (487). Germany continues to be the Company's most important market as the majority of the sales were generated there being 97 (88)% of sales in the quarter. The German market continues to develop positively, as a result of increased market investments and an increased presence in the form of our own sales organization, and increased by 124% in the quarter compared to the second quarter 2015. The other markets take time to develop.

In the quarter 4,016 (2,096) electrodes were sold, an increase of 92%. Electrode sales in Germany increased in the quarter by 212%.

Operating profit/loss

The operating loss for the period April - June 2016 amounted to TSEK 14,472 (11,369), an increased loss of TSEK 3,103. The main reasons for this are, increased investments in sales and marketing activities related to the build-up of our own organization in Germany (the subsidiary was formed in Q1 2015), expenses related to the ongoing PMA process, product development and expenses related to the improvement of the electrode production process.

The gross margin continues to improve and was 30.1 (negative 34.5)% for the period. The main reasons for this were that the bulk of the sales was in the Company's direct market Germany and a reduced cost of goods for the electrode.

Sales and marketing expenses rose by TSEK 1,911 and amounted to TSEK 6,951 (5,040) for the period. The increase is primarily attributable to expenses for the commercialization of Nevisense® and the increase of resources for sales and marketing in both Sweden and Germany.

Administration expenses for the period amounted to TSEK 2,312 (3,263), a decrease of TSEK 951 primarily thanks to last year's IPO process and that during 2016 a function has been transferred to Development (TSEK 607 included in the expenses for 2015).

Development expenses for the period amounted to TSEK 5,675 (2,726), an increase of TSEK 2,949, of which TSEK 607 are attributable to the transferred function from administration in 2016. Otherwise, expenses increased primarily due to the ongoing PMA process, new product development projects, the ongoing project to automate the production of electrodes and increased resources connected to these activities.

Cash flow, investments and financial position

At the start of the quarter, cash and cash equivalents amounted to TSEK 122,241 and, at the end of the period, to TSEK 108,786.

Cash flow from current operations for the period was negative to the amount of TSEK 13,112 (13,858), of which changes in working capital amounted to a positive TSEK 1,210 (negative 2,517). The negative operating cash flow, excluding changes in working capital, decreased mainly due to the above-described cost increases related to increased market investments. Total cash flow for the period was negative to the amount of TSEK 13,403 (positive 148,262). Last year's cash flow was positively affected by the new share issue raising MSEK 154.2 (net) in the second quarter.

Investments in tangible assets for the period amounted to TSEK 336 (275) and mainly involved investments in demo-instruments and office equipment. Investments in intangible assets for the period amounted to TSEK 0 (0).

Depreciation of tangible assets was charged against earnings for the period to the value of TSEK 77 (46).

First half-year

Net Sales

Net sales for the first half-year of 2016 amounted to TSEK 2,921 (1,975), an increase of 48%. Of this, sales of instruments accounted for TSEK 1,081 (976) and sales of tests for TSEK 1,840 (999). Germany continues to be the Company's most important market as the majority of the sales were generated there being 90 (76)% of sales in the period. The German market continues to develop positively as a result of increased market acceptance, driven by market investments and an increased presence in the form of our own sales organization. Sales in Germany increased by 76% in the period compared to the corresponding period 2015.

In the period 6,432 (3,904) electrodes were sold, an overall volume increase of 65%. Electrode sales in Germany increased by 129% by volume.

Operating profit/loss

The operating loss for the period January - June 2016 amounted to TSEK 26,073 (20,537), an increased loss of TSEK 5,536. The main reasons for this are, increased investments in sales and marketing activities related to the commercialization of the Company's product, the build-up of our own organization in Germany (the subsidiary was formed in Q1 2015), expenses related to the ongoing PMA process, product development and expenses related to the improvement of the production process for the electrodes.

The gross margin continues to improve and was 28.7 (negative 14.6)% for the period. The main reasons for this were that the bulk of the sales was in the Company's direct market Germany and a reduced cost of goods for the electrode.

Sales and marketing expenses rose by TSEK 3,626 and amounted to TSEK 13,034 (9,408) for the period. The increase is primarily attributable to expenses for the commercialization of Nevisense® and the increase of resources for sales and marketing in both Sweden and Germany.

Administration expenses for the period amounted to TSEK 4,520 (5,857), a decrease of TSEK 1,337 thanks to the IPO process during 2015, lower expenses for patents in the period and the fact that during 2016 a function has been transferred to Development (in 2015 TSEK 886 included).

Development expenses for the period amounted to TSEK 9,221 (4,978), an increase of TSEK 4,243 (of which TSEK 886 is attributable to the transferred function). Otherwise expenses increased primarily due to the ongoing PMA process, new product development projects, the ongoing project to automate the production of electrodes and increased resources connected to these activities.

Cash flow, investments and financial position

At the start of the year, cash and cash equivalents amounted to TSEK 133,736 and, at the end of the period, to TSEK 108,786.

Cash flow from current operations for the period was negative to the amount of TSEK 24,359 (23,055), of which changes in working capital amounted to a positive TSEK 1,509 (negative 2,574). The negative operating cash flow, excluding changes in working capital, decreased mainly due to the above-described cost increases related to increased market investments. Total cash flow for the period was negative to the amount of TSEK 24,950 (positive 138,029). The previous year's cash flow was positively affected by the new share issue raising around MSEK 154.2 (net) in the second quarter.

Investments in tangible assets for the period amounted to TSEK 718 (754) and mainly involved investments in a new company car, demonstration instruments and office equipment. Investments in intangible assets for the period amounted to TSEK 0 (0).

Depreciation of tangible assets was charged against earnings for the period to the value of TSEK 131 (74).

Other disclosures

Shareholders

At the end of the period, SciBase Holding AB had approximately 1,250 shareholders, of whom the four largest represented approximately 60.1% of the capital and votes. The total number of shares amounts to 8,284,768. The largest shareholders as of June 30, 2016 were SEB Venture Capital (23%), SEB Pensionsstiftelse (16%), Fouriertransform AB (15%) and Omega Fund IV LP. (7%).

At an extraordinary shareholders meeting held on April 28, 2015 it was resolved to implement an incentive program. The program comprises a maximum of 553,863 warrants of which 392,317 have been allotted so far. The warrants that were allotted to the subsidiary SciBase Intressenter AB, shall thereafter at market value, be allotted to employees, the Board, the CEO and management. For a full description of the program please see the Company's website and the minutes from the EGM on April 28th 2015.

Market overview

Skin cancer is believed to be the most common form of cancer in the world. More than 3.5 million cases of skin cancer are reported every year in the US alone, which is more than the other five most common cancers combined. Currently around 50-60 million formal skin cancer screenings are estimated to be performed annually around the world, of which around 50 million are in SciBase's target geographies. The cost for these 50 million screenings is estimated to be around USD 2 billion. Around 10-15% of patients exhibit lesions that are atypical and can be difficult to judge. Though there is considerable variation, approximately 10% or 5 million lesions are suspicious enough to be excised. These 5 million annual excisions represent SciBase's initial target market where Nevisense could help to improve the quality of the diagnosis.

Of the five million estimated annual excisions performed in SciBase's target markets around 95% or 4.8 million lesions are later found to be benign. Uncertainty in the detection of malignant melanoma due to inexperience and limitations of visual screening methods leads physicians to excise many lesions 'just in case', as physicians do not want to risk missing a melanoma. The excision and biopsy of benign (harmless, i.e. not skin cancers) lesions due to uncertainty of visual screening methods is estimated to cost payers around USD 1.5 billion annually. SciBase estimates that Nevisense could reduce the number of benign lesion excisions by 34-50% (1.6-2.4 million lesions annually) based on the EIS score. These lesions represent around USD 520-770 million in excision costs that could be avoided with SciBase's method. For more information regarding SciBase's products and market see the annual report for 2015 pages 4-8.

Employees

At the end of the period, the number of employees amounted to 20 (14), of whom 30 (36)% were women.

Financing

The Board of Directors regularly reviews the company's existing and forecast cash flows to ensure that the company has the funds and resources necessary to pursue operations and strategic focus adopted by the Board. The company's long-term cash needs are largely determined by how successful the current product will be/is in the market, developments and regulatory events that could affect the company's ability to sell its products or that would affect compensation levels in insurance systems for the use of the company's products as well as the expenditure associated with these efforts.

Based on current forecasts and thanks to the in May 2015 completed new share issue, it is the Board's opinion that the Company currently has the financial resources necessary to conduct operations according to the approved plan for the next 12 months.

Transactions with related parties

In the period, the parent Company SciBase Holding AB has invoiced TSEK 2,153 (1,077) to the fully owned subsidiary SciBase AB, which corresponds to a 100% of the parent Company's turnover in the period. In the period there were no other transactions with related parties that had any material impact on the Group or Parent Company's position and earnings during the reporting period.

Risks and uncertainty

The principal risks and sources of uncertainty for SciBase include, albeit not exclusively, financial risks, such as the future earnings trend, financing, and currency and credit risks. In addition to market risks, there are also risks associated with SciBase's operations, such as obtaining necessary approval from authorities, product development, patents and intellectual property rights, product responsibility and forward looking info. Nor are there any guarantees that the Company will be able to secure the financial resources necessary to conduct its operations. Further information on the Company's risk exposure can be found on pages 26-28 of SciBase's 2015 Annual Report.

Parent Company

SciBase Holding AB (publ), corporate identity number 556773-4768, is the Parent Company of the Group. The company was formed in 2009 following a restructuring of the Group. The actual operations are conducted by the fully owned subsidiary SciBase AB.

As per June 30, 2016, the Parent Company had three employees, the CEO and the Groups finance department and the operations consists of consulting activities for the rest of the Group. The company's main task is of a financial nature – to fund the Group's operational activities.

Net sales for the period reached TSEK 2,153 (1,077). The loss for the period amounted to TSEK 1,799 (1,576). The Company's net sales consist of invoiced consultancy fees to the fully owned subsidiary SciBase AB.



The financial tangible assets have increased due to shareholders' contributions to the fully owned subsidiary SciBase AB.

Significant events during the second quarter

SciBase and Ginolis agreed that SciBase would insource the strategically important production of the disposable electrode from Ginolis AB. The companies have mutually agreed to transfer the manufacturing to SciBase on completion of the next milestone in the stepwise automation of the production process. During the period and as a preparatory step two former Ginolis employees, who have been involved in the production of the electrodes, were employed by SciBase. The production itself will continue from Ginolis' current premises in Uppsala. By integrating the manufacturing of the electrodes into SciBase's operations we expect to see improvements in both product development and manufacturing of the electrode. When using Nevisense, a new electrode is required for every patient examined. SciBase's business model is based on selling instruments, but the major potential lies in the continuous use as it generates revenues from the sale of the single-use electrodes. During the first half of 2016 SciBase increased sales of the electrodes with 65%. The company does not expect the margin, which improved strongly in 2016, to be affected notably short-term. The transfer of the production was completed after the period.

The AGM was held on May 16, 2016. The meeting resolved to adopt the profit and loss account and balance sheet for the group and the Company included in the annual report, to adopt the profit and loss distribution, to discharge the board members and managing director from liability, re-election of Tord Lendau, Per Aniansson, Carsten Browall, Renee Aguilar-Lucander and new election of Andreas Pennervall as board-members. The meeting also decided upon the board-fees and resolved to adopt guidelines for determination of salary and other remuneration to senior management in accordance the Board's proposal. Furthermore, the meeting resolved to adopt principles for the appointment the nominating committee for the annual general meeting 2017. The meeting resolved unanimously to authorize the board of directors to, during the time until the next annual general meeting, decide upon issuances of

new shares, issuance of warrants and/or convertibles. New issues of shares and issues of warrants and/or convertibles may occur with or without preferential rights for shareholders of the Company and payment may be used for strategic acquisitions, and may be made either in cash and/or by way of set-off or contribution in kind or otherwise on specific terms. The number of shares issued, or number of shares created in connection with exercise of warrants or conversion of convertibles, shall not exceed 820,000.

SciBase participated in the Euromelanoma-week May 9-13, a European initiative to highlight skin-cancer, by offering selected Swedish clinics Nevisense to improve the diagnosis of malignant melanoma.

On April 25 the Annual Report for 2015 for the Group was published.

Significant events after the period

In Germany the hundredth clinic installed a Nevisense device.

Consolidated Income Statement

SEK 000'	Apr 1 - Jun 30		Jan 1 - Jun 30		July 1, 2015 -	
	2016	2015	2016	2015	Jun 30, 2016 Rolling-12	Jan 1 - Dec 31 2015
Net sales	1 855	918	2 921	1 975	5 097	4 151
Cost of goods sold	-1 297	-1 235	-2 083	-2 264	-3 867	-4 048
Gross Profit/Loss	558	-317	838	-289	1 230	103
Sales and marketing expenses	-6 951	-5 040	-13 034	-9 408	-24 218	-20 592
Administration expenses	-2 312	-3 263	-4 520	-5 857	-9 638	-10 975
Development expenses	-5 675	-2 726	-9 221	-4 978	-14 803	-10 560
Other operating income	-	-	18	18	146	146
Other operating expenses	-92	-23	-154	-23	-229	-98
Operating Income	-14 472	-11 369	-26 073	-20 537	-47 512	-41 976
Financial income	5	438	9	438	36	465
Financial expenses	-1	-8	-3	-19	-5	-21
Profit/Loss before taxes	-14 468	-10 939	-26 067	-20 118	-47 481	-41 532
Income tax	-	-	-1	-	-1	-
Profit/Loss for the period	-14 468	-10 939	-26 068	-20 118	-47 482	-41 532
Net Profit/Loss attributable to:						
Parent company shareholders	-14 468	-10 939	-26 068	-20 118	-47 482	-41 532
Earnings per share based on Net Profit/Loss attributable to parent company shareholders (in SEK/share)						
Profit/loss per share (before and after dilution)*	-1,75	-1,80	-3,15	-3,63	-5,73	-6,01
Average number of shares outstanding	8 284,77	6 084,77	8 284,77	5 534,77	8 284,77	6 909,77

*Profit/loss per share after dilution is not reported, since this would imply improved earnings per share

Consolidated statement of comprehensive income

SEK 000'	Apr 1 - Jun 30		Jan 1 - Jun 30		July 1, 2015 -	
	2016	2015	2016	2015	Jun 30, 2016 Rolling-12	Jan 1 - Dec 31 2015
Profit/loss for the period	-14 468	-10 939	-26 068	-20 118	-47 482	-41 532
<i>Other comprehensive income for the period:</i>						
<i>Items that have or may be reclassified to profit or loss:</i>						
Changes in fair value on financial assets that can be sold	-2	0	-2	0	-5	-3
Tax effect attributable to changes in fair value on financial assets that can be sold	0	0	0	0	1	1
Translation differences on foreign operations	40	21	80	24	38	-18
Sum other comprehensive income	38	21	78	24	34	-20
Total comprehensive income for the period	-14 430	-10 918	-25 990	-20 094	-47 448	-41 552
Total comprehensive income attributable to:						
Parent company shareholders	-14 430	-10 918	-25 990	-20 094	-47 448	-41 552



Consolidated summary statement of financial position

SEK 000'	30-jun		Dec 31
	2016	2015	2015
ASSETS			
<i>Fixed Assets</i>			
Intangible assets	-	-	-
Tangible fixed assets	9 916	9 479	9 446
Financial fixed assets	1 180	1 185	1 182
Total Tangible Assets	11 096	10 664	10 628
<i>Current Assets</i>			
Inventory	4 962	2 297	5 367
Current tax receivable	846	619	540
Receivables	1 169	608	734
Other current receivables	2 329	2 698	2 786
Cash equivalents	108 786	165 595	133 736
Total Current Assets	118 092	171 817	142 623
Total Assets	129 188	182 481	153 251
Shareholders' Equity and Liabilities			
Shareholders' equity attributable to parent company shareholders	119 719	166 789	145 709
<i>Longterm Liabilities</i>			
Deferred tax liability	26	27	26
Total Longterm Liabilities	26	27	26
<i>Current Liabilities</i>			
Accounts payable	3 740	11 504	3 224
Other current liabilities	5 703	4 161	4 292
Total Current Liabilities	9 443	15 665	7 516
Total Liabilities	9 469	15 692	7 542
Total shareholders' equity and liabilities	129 188	182 481	153 251



Consolidated change in shareholders' equity

SEK 000'	Share Capital	Other Capital Contributions	Reserves	Accumulated Loss	Total shareholders' Equity attributable to parent company shareholders
Opening balance Jan 1, 2015	22 032	282 474	94	-271 955	32 645
Profit/loss for the period				-20118	-20 118
Other comprehensive income			24		24
Total comprehensive income	0	0	24	-20 118	-20 094
<i>Transactions with shareholders:</i>					
Reduction of sharecapital	-3 588	3 588			0
New share issue	12 210	152 790			165 000
Issue expenses		-10831			-10 831
Warrants		69		0	69
Total transactions with shareholders	8 622	145 616	0	0	154 238
Closing balance June 30, 2015	30 654	428 090	118	-292 073	166 789
Opening balance Jan 1, 2016	30 654	428 468	74	-313 487	145 709
Profit/loss for the period				-26 068	-26 068
Other comprehensive income			78		78
Total comprehensive income	0	0	78	-26 068	-25 990
<i>Transactions with shareholders:</i>					
Total transactions with shareholders	0	0	0	0	0
Closing balance June 30, 2016	30 654	428 468	152	-339 555	119 719

Consolidated summary statement of cash flows

SEK 000'	Apr 1 - Jun 30		Jan 1 - Jun 30		July 1, 2015 -	
	2016	2015	2016	2015	Jun 30, 2016 Rolling-12	Jan 1 - Dec 31 2015
Net Income before taxes	-14 468	-10 939	-26 067	-20 118	-47 481	-41 532
Adjustments for non-cashflow items	146	-402	200	-363	225	-338
Paid Income Tax	-	-	-1	-	-1	-
Cashflow from operating activities before change in working capital	-14 322	-11 341	-25 868	-20 481	-47 257	-41 870
<i>Cashflows from changes in working capital</i>						
Change in Inventory	461	-1 227	405	-1 352	-2 665	-4 422
Change in Receivables	-804	-572	-824	-806	-420	-402
Change in Liabilities	1 553	-718	1 928	-416	2 450	106
Total change in working capital	1 210	-2 517	1 509	-2 574	-635	-4 718
Cashflow from operating activities	-13 112	-13 858	-24 359	-23 055	-47 892	-46 588
<i>Investment activities</i>						
Acquisitions of Fixed Assets	-291	-786	-591	-1 822	-674	-1 905
Divestment of fixed assets	-	-	-	-	108	108
Cashflow from investment activities	-291	-786	-591	-1 822	-566	-1 797
<i>Financing activities</i>						
New share issues	-	165 000	-	165 000	0	165 000
Expenses related to new share issues	-	-2 163	-	-2 163	-8 670	-10 833
Warrants	-	69	-	69	378	447
Cashflow from financing activities	0	162 906	0	162 906	-8 292	154 614
Cashflow for the period	-13 403	148 262	-24 950	138 029	-56 750	106 229
Cash equivalents at start of the year	122 241	17 313	133 736	27 566	165 595	27 566
Exchange rate differences in cash equivalents	-52	20	0	0	-59	-59
Cash equivalents at end of the period	108 786	165 595	108 786	165 595	108 786	133 736



Income statement, Parent Company

SEK 000'	Apr 1 - June 30		Jan 1 - June 30		July 1 2015 -	
	2016	2015	2016	2015	June 30, 2016 Rolling-12	Jan 1 - Dec 31 2015
Net Sales	1 076	1 077	2 153	1 077	4 306	3 230
Administration expenses	-1 840	-2 463	-3 952	-2 653	-7 559	-6 260
Operating Profit/loss	-764	-1 386	-1 799	-1 576	-2 176	-3 030
<i>Earnings from financial items:</i>						
Financial income	0	-	0	-	0	-
Financial expenses	-	-	-	-	-	-
Profit/loss after financial items	-764	-1 386	-1 799	-1 576	-2 176	-3 030
Taxes	-	-	-	-	-	-
Profit/loss for the period	-764	-1 386	-1 799	-1 576	-2 176	-3 030

Statement of other comprehensive income, Parent Company

SEK 000'	Apr 1 - June 30		Jan 1 - June 30		July 1 2015 -	
	2016	2015	2016	2015	June 30, 2016 Rolling-12	Jan 1 - Dec 31 2015
Profit/loss for the period	-764	-1 386	-1 799	-1 576	-2 176	-3 030
<i>Other comprehensive income</i>	-	-	-	-	-	-
Total other comprehensive income	-	-	-	-	-	-
Total comprehensive income	-764	-1 386	-1 799	-1 576	-2 176	-3 030



Summary Balance Sheet, Parent Company

SEK 000'	June 30		Dec 31
	2016	2015	2015
ASSETS			
<i>Fixed Assets</i>			
Financial Tangible Assets	164 077	115 302	137 647
Total Fixed Assets	164 077	115 302	137 647
<i>Current Assets</i>			
Current receivables and prepaids	3 297	6 755	6 119
Cash equivalents	105 731	163 394	130 472
Total Current Assets	109 028	170 149	136 591
TOTAL ASSETS	273 105	285 451	274 238
SHAREHOLDERS' EQUITY AND LIABILITIES			
<i>Shareholder's equity</i>			
Share Capital	30 654	30 654	30 654
Other capital contributions	428 521	428 521	428 521
Retained earnings	-186 221	-183 192	-183 191
Profit/Loss for the period	-1 799	-1 576	-3 030
Shareholders equity	271 155	274 407	272 954
Current liabilities	1 950	11 044	1 284
Total liabilities	1 950	11 044	1 284
TOTAL SHAREHOLDERS' EQUITY AND LIABILITIES	273 105	285 451	274 238

Notes

Not 1 Accounting principles

The Group's interim report has been prepared in accordance with IAS 34 Interim Financial Reporting and the Annual Accounts Act. For the Parent Company, the interim report has been prepared in accordance with the Annual Accounts Act and the Swedish Securities Market Act in accordance with the provisions of RFR 2. For both the Group and the Parent Company the same accounting principles and bases for calculation have been applied as in its most recent Annual Report. Significant accounting and valuation principles are detailed on pages 37-43 of the consolidated annual report for 2015.

New or revised IFRS standards and interpretations by the IFRS Interpretations Committee have not had an effect on the Group's or Parent Company's earnings, financial position or disclosures.

Note 2 Fair value of financial instruments

Current receivables and liabilities

For current receivables and liabilities, such as accounts receivable and accounts payable with a maturity of less than six months, the carrying amount is considered to reflect fair value.

Financial fixed assets

Financial fixed assets, which consist of cash funds, are traded in an active market and fair value is calculated based on the last quoted bid price on the balance sheet date. These assets are included in Level 1 of the fair value hierarchy.

Other non-current liabilities

Other non-current liabilities consist of liabilities to subcontractors. Fair value corresponds to the book value and these liabilities are included in Level 2 of the fair value hierarchy. The liability to the subcontractor has been regulated since the second quarter of 2015.

Note 3 Pledged Assets

The Parent Company issued a capital adequacy guarantee to its wholly owned subsidiary SciBase AB for a maximum of SEK 55,000,000 that is valid until the end of 2016. The corresponding agreement was in-place in 2015 and 2014 as well.

Note 4 Seasonal effects

To a certain extent, SciBase's sales and operating profit are expected to be dependent on seasonal variation that the company cannot influence. In the third quarter, due to

the vacation period, the number of tests performed is expected to decrease and consequently the company's sales are also expected to dip.

Note 5 Information regarding operating segments

The Group has today only one operating segment, detection of malignant melanoma. Follow-ups are done on the geographical areas, Europe/Rest of the World, US/NorthAmerica and Asia/Oceania.

Second quarter

Segment Europa/Rest of the World

Net sales for the segment during the period amounted to TSEK 1,855 (895) of which Germany accounted for 97 (90)%. In the period the focus for the sales and marketing effort has continued to be Germany with the Company's own sales organization. However, a considerable effort have also been made to get the other markets to start generating sales. Gross profit in the segment amounted to a profit of TSEK 558 (loss of 289).

Other segments

Net sales for the segment during the year amounted to TSEK 0 (23). In this segment, it is only in Australia that the company is present, via a distributor. Gross profit in the segment amounted to TSEK 0 (loss of 28).

The Group has chosen to merge the segments North America/USA and Asia/Oceania into Other Segments since they do not amount to a substantial portion of the total.

First half-year

Segment Europa/Rest of the World

Net sales for the segment during the period amounted to TSEK 2,921 (1,952) of which Germany accounted for 90 (77)%. In the period the focus for the sales and marketing effort has continued to be Germany with the Company's own sales organization. However, a considerable effort have also been made to get the other markets to start generating sales. Gross profit in the segment amounted to a profit of TSEK 838 (loss of 261).

Other segments

Net sales for segment during the year amounted to TSEK 0 (23). In this segment, it is only in Australia that the company is present, via a distributor. Gross profit in the segment amounted to TSEK 0 (loss of 28).

The Group has chosen to merge the segments North America/USA and Asia/Oceania into Other Segments since they do not amount to a substantial portion of the total.

SEK 000'	Apr 1 - June 30, 2016			Apr 1 - June 30, 2015		
	Europe/ Rest of the World	Other Segments	Total	Europe/ Rest of the World	Other Segments	Total
Segment - Net sales	1 855	-	1 855	895	23	918
Sales between segments	-	-	-	-	-	-
Net sales from external customers	1 855	-	1 855	895	23	918
Cost of goods	-1 297	-	-1 297	-1 184	-51	-1 235
Gross Profit/Loss	558	0	558	-289	-28	-317
Operating expenses			-15 030			-11 052
Operating profit/Loss			-14 472			-11 369
Financial Income			5			438
Financial Expenses			-1			-8
Group earnings - before tax			-14 468			-10 939

SEK 000'	Jan 1 - June 30, 2016			Jan 1 - June 30, 2015		
	Europe/ Rest of the World	Other Segments	Total	Europe/ Rest of the World	Other Segments	Total
Segment - Net sales	2 921	-	2 921	1 952	23	1 975
Sales between segments	-	-	-	-	-	-
Net sales from external customers	2 921	-	2 921	1 952	23	1 975
Cost of goods	-2 083	-	-2 083	-2 213	-51	-2 264
Gross Profit/Loss	838	0	838	-261	-28	-289
Operating expenses			-26 911			-20 248
Operating profit/Loss			-26 073			-20 537
Financial Income			9			438
Financial Expenses			-3			-19
Group earnings - before tax			-26 067			-20 118



Signatures

The Board of Directors and the President provide their assurance that this interim report provides an accurate view of the operations, position and earnings of the Group and the Parent Company, and that it also describes the principal risks and uncertainties faced by the Parent Company and the companies included within the Group.

[SciBase Holding AB]
Stockholm, August 19, 2016

Tord Lendau
Chairman of the Board

Per Aniasson
Board member

Carsten Browall
Board member

Renee Lucander
Board member

Stig Ollmar
Board member

Andreas Pennervall
Board member

Simon Grant
President and CEO

Contactperson:
Michael Colérus, CFO

This information is information that SciBase Holding AB is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact person set out above, at 08.00 CET on August 19, 2016.

This interim report has not been subject to review by the Company's auditors.

Quarterly overview

THE GROUP	2016			2015			2014		
	Q2	Q1	Q4	Q3	Q2	Q1	Q4	Q3	Q2
Net sales, SEK ths	1 855	1 066	1 181	995	918	1 057	460	818	258
Gross margin, %	30,1%	26,3%	18,4%	17,6%	-34,5%	2,6%	-41,5%	-42,8%	-10,1%
Equity/Asset ratio, %	92,7%	94,4%	95,1%	94,2%	91,4%	73,0%	78,5%	84,4%	84,8%
Net indebttness, multiple	0,08	0,06	0,05	0,06	0,09	0,37	0,27	0,19	0,18
Cash equivalents, SEK ths	108 786	122 241	133 736	147 661	165 595	17 313	27 566	37 176	46 903
Cashflow from operating activities, SEK ths	-13 112	-11 247	-13 864	-9 669	-13 858	-9 197	-9 290	-9 578	-7 959
Earnings per share (before and after dilution), SEK	-1,75	-1,40	-1,35	-1,24	-1,80	-1,84	-2,06	-1,59	-2,32
Shareholder's equity per share, SEK	14,45	16,19	17,59	18,93	27,41	4,71	6,55	8,61	10,20
Average number of shares, 000' *	8 285	8 285	8 285	8 285	6 085	4 985	4 985	4 985	4 985
Number of shares at closing of period, 000' *	8 285	8 285	8 285	8 285	8 285	4 985	4 985	4 985	4 985
Share price at end of period, SEK	17,20	23,50	31,00	30,80	43,00	-	-	-	-
Average number of employees	19	18	15	15	13	14	11	12	12

*Adjusted for in May 2015 performed reversed split, 40:1

Definitions

Financial key ratios

- TSEK: SEK 000'
- Gross margin, %: Gross profit divided by net sales.
- Operating profit: Operating income less operating expenses.
- Operating margin, %: Operating profit divided by income.
- Equity/assets ratio: Equity at the end of the period divided by total assets at the end of the period.
- Debt/equity ratio: Total liabilities in relation to equity.
- Earnings per share for the period before dilution: Profit for the period divided by average number of shares before dilution.
- Earnings per share for the period after dilution: Profit for the period divided by average number of shares after dilution. Earnings per share after dilution is the same as before dilution because potential ordinary shares do not cause to dilution.
- Shareholders' equity per share: Equity divided by average number of shares.
- Dividend per Share: Dividend for the period divided by average number of shares after dilution.
- Number of shares before dilution at the end of the period: Number of shares in issue before dilution at the end of the period.
- Average number of shares before dilution: Average number of shares during the period before dilution.
- Average number of shares after dilution: Average number of shares in issue after dilution is the same as before dilution because potential ordinary shares do not cause to dilution.
- Number of employees (average): Weighted average number of employees in the relevant period.
- IFRS: International Financial Reporting Standards

Industry specific glossary

- CE labeling: A mandatory conformity marking to show that products sold within the European Economic Area (EEA) since 2008 fulfills the requirements of the acquis. CE labeling is also included on products sold outside the EEA but that are produced in the EEA, or intended for sale there.
- Dermatoscopy or Dermoscopy: Examination of skin lesions with a dermatoscope, a strong magnifying glass with a built-in light source.
- Electrical Impedance Spectroscopy (EIS): A measure of the overall impedance occurring in tissue when alternating current is applied at a series of alternating frequencies. This is measured by transmitting an imperceptible alternating current between the bands on the electrode, which is mounted on the tip of the probe and measures the current.
- FDA: The US Food and Drug Administration is the US authority controlling all aspects of the development, manufacture and commercialization of pharmaceutical products and medical devices in the United States.
- Malignant melanoma: The most dangerous form of skin cancer, consisting of cancer in pigment-producing melanocytes.
- Unnecessary excision: The removal of benign skin lesions/birthmarks.
- Nevi: Lesion.
- PMA: Form of approval required for all Class III devices for FDA approval in the USASA



Simon Grant
CEO
+46 72 887 43 99
simon.grant@SciBase.com

Read more about the company and its operations at our website >> www.SciBase.com



Michael Colérus
CFO
+46 70 341 34 72
michael.colérus@SciBase.com

Future reporting dates

Interim report July – September November 14, 2016

Year-end report 2016, February 17 2017

